Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven P Treon

Showing results (251-260 of 323) with videos related to

Pageof 33
Sort By:
Hemasphere|August 18, 2020
Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 PandemicDipti Talaulikar, Ranjana H Advani, Andrew R Branagan, et al.
Blood Advances|April 15, 2026
Zanubrutinib and pirtobrutinib show synergistic killing and suppression of BTK signaling in MYD88-mutated lymphoma cellsDominic Pizzarella, Amanda Kofides, John M Hatcher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 4, 2021
Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE StudyChristian Buske, Alessandra Tedeschi, Judith Trotman, et al.
Blood|September 1, 2007
The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemiaXavier Leleu, Xiaoying Jia, Judith Runnels, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 12, 2016
Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation StatusMichele Cea, Antonia Cagnetta, Chirag Acharya, et al.
Cell Chemical Biology|November 14, 2017
A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase DegraderHai-Tsang Huang, Dennis Dobrovolsky, Joshiawa Paulk, et al.
Seminars in Hematology|May 17, 2025
Report of Consensus Panel 4 from the 12th International Workshop on Waldenström's Macroglobulinemia on the management of patients with non-IgM lymphoplasmacytic lymphomaAlessandra Tedeschi, Rebecca Auer, Francesco Autore, et al.
American Journal of Hematology|December 24, 2019
Deepening of response after completing rituximab-containing therapy in patients with Waldenstrom macroglobulinemiaJorge J Castillo, Joshua N Gustine, Andrew Keezer, et al.
Cancer Research|April 19, 2007
Proteomic analysis of waldenstrom macroglobulinemiaEvdoxia Hatjiharissi, Hai Ngo, Alexey A Leontovich, et al.
Hemasphere|July 22, 2021
Diagnostic Next-generation Sequencing Frequently Fails to Detect MYD88<sup>L265P</sup> in Waldenström MacroglobulinemiaAmanda Kofides, Zachary R Hunter, Lian Xu, et al.
Pageof 33

Showing results (251-260 of 323) with videos related to

Sort By:
Pageof 33
Hemasphere|August 18, 2020
Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 PandemicDipti Talaulikar, Ranjana H Advani, Andrew R Branagan, et al.
Blood Advances|April 15, 2026
Zanubrutinib and pirtobrutinib show synergistic killing and suppression of BTK signaling in MYD88-mutated lymphoma cellsDominic Pizzarella, Amanda Kofides, John M Hatcher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 4, 2021
Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE StudyChristian Buske, Alessandra Tedeschi, Judith Trotman, et al.
Blood|September 1, 2007
The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemiaXavier Leleu, Xiaoying Jia, Judith Runnels, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 12, 2016
Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation StatusMichele Cea, Antonia Cagnetta, Chirag Acharya, et al.
Cell Chemical Biology|November 14, 2017
A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase DegraderHai-Tsang Huang, Dennis Dobrovolsky, Joshiawa Paulk, et al.
Seminars in Hematology|May 17, 2025
Report of Consensus Panel 4 from the 12th International Workshop on Waldenström's Macroglobulinemia on the management of patients with non-IgM lymphoplasmacytic lymphomaAlessandra Tedeschi, Rebecca Auer, Francesco Autore, et al.
American Journal of Hematology|December 24, 2019
Deepening of response after completing rituximab-containing therapy in patients with Waldenstrom macroglobulinemiaJorge J Castillo, Joshua N Gustine, Andrew Keezer, et al.
Cancer Research|April 19, 2007
Proteomic analysis of waldenstrom macroglobulinemiaEvdoxia Hatjiharissi, Hai Ngo, Alexey A Leontovich, et al.
Hemasphere|July 22, 2021
Diagnostic Next-generation Sequencing Frequently Fails to Detect MYD88<sup>L265P</sup> in Waldenström MacroglobulinemiaAmanda Kofides, Zachary R Hunter, Lian Xu, et al.
Pageof 33